Author:
Chong Huey Yi,Choon June Wai Yee,Ang Wei Chern,Lee Kenneth Kwing Chin
Abstract
Introduction: Untreated iron deficiency (ID) can lead to severe anaemia, requiring blood transfusion, or increased mortality risk. Globally intravenous (IV) iron is increasingly recognised as a recommended option for patients. This study aims to evaluate the budget impact associated with introducing a new intravenous (IV) iron, ferric derisomaltose (Monofer® [IIM]) as one of the treatment options for the management of ID in the Ministry of Health Malaysia (MOHM) setting. Methods: A 5-year budget impact model was developed from 2020 to 2024 for patients with ID that require a high iron dose (≥500 mg), using the perspective of MOHM. The model was built with four external medical specialists, each with experience and deep knowledge of ID management, to support estimations on the future development of iron use in Malaysia. Results: Compared to the current market mix with the existing IV iron products (i.e., iron sucrose and iron dextran), a cost-saving of MYR 53,910 could be achieved with the introduction of IIM in 2020. The uptake of IIM into MOHM over five years is estimated to lead to an overall budget saving of MYR 11,837,524 over a 5-year time horizon. Conclusion: The use of IIM in place of the current IV iron products in MOHM resulted in a significant cost saving by reducing the number of visits required to achieve the targeted iron dose and the shorter IV infusion time with IIM.
Publisher
Universiti Putra Malaysia
Reference30 articles.
1. 1. Muñoz M, Gómez-Ramírez S, Besser M, Pavía J, Gomollón F, Liumbruno GM, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017;15(5):422-437. doi: 10.2450/2017.0113-17.
2. 2. Bouri S, Martin J. Investigation of iron deficiency anaemia. Clin Med (Lond). 2018;18(3):242-244. doi: 10.7861/clinmedicine.18-3-242
3. 3. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NICE Guideline NG208). London: NICE;2019.
4. 4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001062.
5. 5. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211-22. doi: 10.1093/ecco-jcc/jju009.